Booting Earth Optimization System
Thank you for your patience. Your civilization is very important to us.
Dihydroartemisinin-Piperaquine
Treatment for Malaria
Typical Dosage: Weight-based, typically once daily for 3 days
Effectiveness
96%
Safety Score
70%
Clinical Trials
143
Participants
100K
Comparative Safety Scale(Higher is safer)
Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
70
DangerousModerateSafe
Treatment Details
Dosage Range
Weight-based, typically once daily for 3 days
Time to Effect
24-48 hours
Treatment Duration
3 days
Evidence Quality
HIGHConfidence Score
88%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$10
Monitoring:$50
Side Effect Mgmt:$10
Total Annual:$70
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
EXCELLENTQALYs Gained
0.08
Outcome-Based Costs
Cost per Responder
$72.9
Cost per Remission
$72.9
Comparison vs Artemether-Lumefantrine
Cost Difference
$0/year
Same cost
QALY Difference
0.00 QALYs
Same outcomes
Dominance
No dominance
Dihydroartemisinin-Piperaquine Outcomes
for Malaria
Efficacy Outcomes
Overall Effectiveness
+96%
Response Rate
+96%
Remission Rate
+96%
Common Side Effects
Headache
+15%
Dizziness
+10%
Nausea/Vomiting
+10%
Abdominal pain
+10%
Sources:
WARNING: LIMITED TRIALS AVAILABLE
You can search for trials, but you probably can't join any because the 1% Treaty hasn't passed yet. Most trials are severely limited by lack of funding and bureaucratic barriers. Help change this!
Active Clinical Trials
3 active trials recruiting for Dihydroartemisinin-Piperaquine in Malaria
Targeted Antimalarial Drug Administration for Seasonal Migrant Populations in Amhara Region, Ethiopia
NCT06516042ACTIVE NOT RECRUITINGPHASE3
10.3K participants
INTERVENTIONAL
Gonder, Ethiopia
Started: Aug 21, 2024
Focal Mass Drug Administration for the Prevention of Malaria in Pregnancy
NCT07021430NOT YET RECRUITINGEARLY_PHASE1
300 participants
INTERVENTIONAL
Kasese, Uganda
Started: Apr 1, 2026
Intermittent Preventive Treatment of Malaria in School-age Children to Decrease Community Transmission
NCT07246525NOT YET RECRUITINGPHASE4
4.8K participants
INTERVENTIONAL
Kampala, Uganda
Started: Aug 1, 2026
Completed Clinical Trials
16 completed trials for Dihydroartemisinin-Piperaquine in Malaria
Dihydroartemisinin-piperaquine and Primaquine for Uncomplicated Plasmodium Falciparum Cases
NCT01392014COMPLETEDPHASE4
374 participants
INTERVENTIONAL
Lampung, Indonesia
Started: Dec 1, 2008
Efficacy and Safety of Dihydroartemisinin-piperaquine (DHP) for the Treatment of Uncomplicated Malaria
NCT02353494COMPLETED
130 participants
OBSERVATIONAL
Timika, Indonesia
Started: Mar 1, 2015
Cardiac Safety of Repeated Doses of Dihydroartemisinin-Piperaquine for the Use in Mass Treatment Campaigns
NCT02605720COMPLETEDPHASE3
78 participants
INTERVENTIONAL
Londolovit, Papua New Guinea
Started: Sep 1, 2015
Comparison Between 7 and 14 Day Primaquine Combined With Dihydroartemisinin-piperaquine or 3 Day Chloroquine Radical Cure of P. Vivax (BPD)
NCT01640574COMPLETEDPHASE3
680 participants
INTERVENTIONAL
Mae Sot, Thailand
Started: Feb 1, 2012
Post-discharge Malaria Chemoprevention(PMC) Study
NCT02671175COMPLETEDPHASE3
1.05K participants
INTERVENTIONAL
Homa Bay, Kenya +8 more
Started: May 20, 2016
Malaria in Early Life Study
NCT02001428COMPLETEDNA
757 participants
INTERVENTIONAL
Timika, Indonesia
Started: Jul 21, 2014
Dihydroartemisinin-piperaquine for Seasonal Malaria Chemoprophylaxis in Tanzania
NCT05874869COMPLETEDNA
13.8K participants
INTERVENTIONAL
Dar es Salaam, Tanzania
Started: Jul 1, 2020
RHOST-cRCT, Reactive Household-based Self-administered Treatment Against Residual Malaria Transmission
NCT02878200COMPLETEDNA
2.24K participants
INTERVENTIONAL
North Bank Region, The Gambia
Started: Nov 4, 2016
Malaria Active Epidemiology and Treatment Study
NCT01280162COMPLETEDNA
222 participants
INTERVENTIONAL
Anlong Veaeng, Cambodia
Started: Sep 1, 2010
Evaluation of the Implementation and Effectiveness of Intermittent Preventive Treatment for Malaria Using Dihydroartemisinin-piperaquine on Reducing Malaria Burden in School Aged Children in Tanzania
NCT04245033COMPLETEDPHASE4
4.1K participants
INTERVENTIONAL
Tanga, Tanzania
Started: Jul 20, 2020
Mass Drug Administration of Dihydroartemisinin-piperaquine + Single Low-dose Primaquine to Accelerate Toward Elimination Activities
NCT04864444COMPLETEDNA
10.7K participants
INTERVENTIONAL
Tambacounda, Senegal
Started: Jun 19, 2021
Mass Drug Administrations of DHA-PQP to Accelerate Towards Malaria Elimination in Magude District, Southern Mozambique
NCT02914145COMPLETEDNA
241K participants
INTERVENTIONAL
Started: Nov 1, 2015
Evaluation of Community-based Mass Screening and Treatment for Malaria in Western Kenya
NCT02987270COMPLETEDPHASE3
90K participants
INTERVENTIONAL
Started: Apr 1, 2013
Surveillance and Treatment With Dihydroartemisinin-piperaquine Plus Primaquine
NCT01878357COMPLETEDPHASE4
1.49K participants
INTERVENTIONAL
Betun, Indonesia
Started: Jun 1, 2013
Dihydroartemisinin-Piperaquine or Sulphadoxine-Pyrimethamine for the Chemoprevention of Malaria in Sickle Cell Anaemia
NCT04844099COMPLETEDPHASE3
723 participants
INTERVENTIONAL
Blantyre, Malawi +2 more
Started: Apr 9, 2021
School-Based Treatment With ACT to Reduce Transmission
NCT02009215COMPLETEDPHASE4
10.7K participants
INTERVENTIONAL
Kampala, Uganda
Started: Feb 1, 2014
Showing 20 of 151 total trials